Omniose

Overview

Omniose is expanding the range of bioconjugate vaccines to fight more bacterial threats
Technology is based on the discovery of a new class of conjugating enzymes, allowing for the efficient production of complex conjugate vaccines

Highlights

Established proof-of-concept for prevention of multiple antibiotic-resistant bacterial infections
Expanded team in April 2022, including Timothy Cooke as CEO and Roman
Fleck as Chairperson, along with a highly experienced SAB, collectively bringing deep industry expertise in infectious disease, drug development, and vaccine development
Next round of funding will allow for enhanced POC and progress toward clinical development

BioGenerator has been integral to the success of Omniose (formerly known as VaxNewMo). BioGenerator was the first organization to encourage and assist with our SBIR/STTR grant applications, helping Omniose secure more than $8M in NIH funding. BioGenerator also made the first equity-based investment in the company and helped us recruit an experienced leadership team to catalyze growth.

Christian Harding
Co-Founder and CSO, Omniose

Omniose

Overview

Highlights

BioGenerator Contributions